(RTTNews) – Japanese biopharmaceutical company AnGes, Inc. on Tuesday announced a collaboration agreement with the pharmaceutical company Brickell Biotech, Inc. (BBI), through which Brickell has the right to expand AnGes’ patented plasma DNA vaccine to save SARS-CoV- 2 (COVID-19) in the United States, South America and some emerging markets.
AnGes is currently conducting phase 1/2 clinical studies with its candidate vaccine in Japan, and knowledge readings are expected until the first quarter of 2021. The effects of these studies will look at AnGes and Brickell’s global progression efforts for this new candidate vaccine.
Under the terms of the agreement, AnGes will continue to lead the progression of its candidate vaccine in Japan and Brickell will provide data and knowledge that can be useful in those progression efforts.
In return, Brickell granted the right to expand and, if approved, market the AnGes DNA vaccine in the United States and some under neglected countries.